Seelos therapeutics to participate in the guggenheim nantucket therapeutics conference

New york , sept. 9, 2022 /prnewswire/ -- seelos therapeutics, inc. (nasdaq: seel), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it will participate in the guggenheim nantucket therapeutics conference, september 27 th to 29th.
SEEL Ratings Summary
SEEL Quant Ranking